GlycoMimetics, Inc. (GLYC)
Chart Events
Performance Outlook
| Previous Close | 2.9700 |
| Open | 2.9600 |
| Bid | 3.0700 x 1800 |
| Ask | 3.0700 x 1100 |
| Day's Range | 2.7400 - 3.0800 |
| 52 Week Range | 1.8200 - 5.1900 |
| Volume | 1,192,599 |
| Avg. Volume | 848,595 |
| Market Cap | 158.6M |
| Beta (5Y Monthly) | 2.40 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1160 |
| Earnings Date | Mar 02, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.25 |
Fair Value
Related Research
- Business Wire
Apollomics, Inc Doses First Patient in Phase 1 Clinical Trial in China of GlycoMimetics’ Uproleselan for the Treatment of AML
GlycoMimetics (Nasdaq: GLYC) today announced that Apollomics has dosed the first patient in China in a Phase 1 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML). In February of this year, Apollomics initiated two Phase 1 study sites in Greater China.
- Motley Fool
GlycoMimetics Inc (GLYC) Q4 2020 Earnings Call Transcript
Image source: The Motley Fool. GlycoMimetics Inc (NASDAQ: GLYC)Q4 2020 Earnings CallMar 2, 2021, 8:30 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood morning, and thank you all for joining the GlycoMimetics call.
- Business Wire
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2020
GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the fourth quarter and year ended December 31, 2020, and highlighted recent Company events, including several accomplishments reported to date in 2021. Cash and cash equivalents at December 31, 2020 were $137.0 million.
